longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Verrica Pharmaceuticals

VRCA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -2.56, within the reasonable range, cheaper than 20.69% of the time in the past 1 years, and the industry ranks 137/257, the industry Median -1.30.

-2.56xP/E
$4.65Stock price
$-1.82Earnings per share
-2.56xP/E
Stock price$4.65Earnings per share$-1.82

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-4.77x
Typical range
-5.69x–-2.50x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-57.64x14.24%$60.18B
BAYZFUSBayer Aktiengesellschaft
-27.45x--$55.39B
BAYRYUSBayer
-27.52x--$55.53B
VTRSUSViatris
-47.91x110.35%$19.68B
ELANUSElanco Animal Health
-57.09x129.36%$11.36B
VREOFUSVIREO GROWTH INC
-168.70x--$11.32B
AXSMUSAxsome Therap
-58.57x27.32%$11.22B
CURLFUSCuraleaf Holdings, Inc.
-150.95x--$7.85B
BLTEUSBelite Bio
-67.02x29.87%$6.86B
DFTXUSDefinium Therapeutics
-14.69x53.32%$5.20B
EWTXUSEdgewise Therapeutics
-25.85x137.29%$5.10B
MANEUSVeraDermics
-43.54x97.39%$4.54B
AMLXUSAmylyx Pharmaceuticals
-28.01x1.76%$4.26B
ELVNUSEnliven Therapeutics
-34.75x1.17%$3.68B
TARSUSTarsus Pharmaceuticals
-74.62x34.09%$3.47B
MBXUSMBX Biosciences
-29.50x30.54%$3.08B
RGCUSRegencell Bioscience
-418.95x--$2.95B
PHVSUSPharvaris BV
-13.45x7.70%$2.67B
GPCRUSStructure Therapeutics
-11.65x104.48%$2.50B
SUPNUSSupernus Pharma
-22.70x70.59%$2.49B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.